title: Development of porous silicon nanocarriers for parenteral peptide delivery.
abstract: Porous silicon (PSi) is receiving growing attention in biomedical research, for example, in drug and peptide delivery. Inspired by several advantages of PSi, herein, thermally oxidized (TOPSi, hydrophilic), undecylenic acid-treated thermally hydrocarbonized (UnTHCPSi, moderately hydrophilic), and thermally hydrocarbonized (THCPSi, hydrophobic) PSi nanocarriers are investigated for sustained subcutaneous (sc) and intravenous (iv) peptide delivery. The route of administration is shown to affect drastically peptide YY3-36 (PYY3-36) release from the PSi nanocarriers in mice. Subcutaneous nanocarriers are demonstrated to be capable to sustain PYY3-36 delivery over 4 days, with the high absolute bioavailability values of PYY3-36. The pharmacokinetic parameters of PYY3-36 are presented to be similar between the sc PSi nanocarriers despite surface chemistry. In contrast, iv-delivered PSi nanocarriers display significant differences between the surface types. Overall, these results demonstrate the feasibility of PSi nanocarriers for the sustained sc delivery of peptides.
authors.affiliation: School of Pharmacy, Pharmaceutical Technology, Faculty of Health Sciences, University of Eastern Finland, 70211 Kuopio, Finland. Miia.Kovalainen@uef.fi
authors.forename: Miia
authors.initials: M
authors.lastname: Kovalainen
authors.forename: Juha
authors.initials: J
authors.lastname: Mönkäre
authors.forename: Martti
authors.initials: M
authors.lastname: Kaasalainen
authors.forename: Joakim
authors.initials: J
authors.lastname: Riikonen
authors.forename: Vesa-Pekka
authors.initials: VP
authors.lastname: Lehto
authors.forename: Jarno
authors.initials: J
authors.lastname: Salonen
authors.forename: Karl-Heinz
authors.initials: KH
authors.lastname: Herzig
authors.forename: Kristiina
authors.initials: K
authors.lastname: Järvinen
mesh_terms: D000279:Administration, Cutaneous; D061605:Administration, Intravenous; D000818:Animals; D001682:Biological Availability; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000737:chemistry; D004337:Drug Carriers / Q000008:administration & dosage / Q000737:chemistry*; D016503:Drug Delivery Systems; D051379:Mice; D008807:Mice, Inbred BALB C; D053758:Nanoparticles / Q000008:administration & dosage* / Q000737:chemistry*; D010446:Peptide Fragments / Q000008:administration & dosage* / Q000737:chemistry*; D019894:Peptide YY / Q000008:administration & dosage* / Q000737:chemistry*; D016062:Porosity; D012825:Silicon / Q000008:administration & dosage / Q000737:chemistry*
chemical_list: D003692:Delayed-Action Preparations; D004337:Drug Carriers; D010446:Peptide Fragments; D019894:Peptide YY; C061785:peptide YY (3-36); D012825:Silicon